Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 4/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | GBA1 | P04062 | 8/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.42 |
| ▸ | TSHR | P16473 | 2/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | KMT5A | Q9NQR1 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9913717 | 0.86 | TSHR (0.56) | KMT2AGBA1TSHRHPGDALDH1A1 | |
| SCHEMBL14725042 | 0.83 | TSHR (0.49) | LMNAMEN1KMT2AMAPK1TSHR | |
| SCHEMBL9913727 | 0.79 | LMNA (0.75) | LMNAMEN1KMT2AGBA1POLB | |
| SCHEMBL9913725 | 0.79 | TSHR (0.57) | KMT2ATSHRHPGDALDH1A1 | |
| SCHEMBL7774828 | 0.73 | LMNA (0.65) | LMNAMEN1KMT2AGBA1POLB | |
| SCHEMBL28887997 | 0.69 | TSHR (0.43) | MAPK1TSHRHPGDSMN1; SMN2ALDH1A1 | |
| SCHEMBL7776363 | 0.69 | LMNA (0.57) | LMNAMEN1KMT2AGBA1POLB | |
| SCHEMBL22356322 | 0.68 | L3MBTL1 (0.51) | LMNAMAPK1TSHRHPGDMAPT | |
| SCHEMBL9913752 | 0.68 | TSHR (0.53) | KMT2AGBA1POLBTSHRALDH1A1 | |
| SCHEMBL13137607 | 0.68 | TSHR (0.42) | LMNAKMT2AMAPK1TSHRHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8198387-B2 | Proton-conducting compound and proton-conducting polymer | NIPPON STEEL CHEMICAL CO., LTD. (JP) | 2012-06-12 | — | — | US | disclosed |
| US-8198387-B2 | Proton-conducting compound and proton-conducting polymer | NIPPON STEEL CHEMICAL CO., LTD. (JP) | 2012-06-12 | — | — | US | disclosed |
| US-20100063249-A1 | PROTON-CONDUCTING COMPOUND AND PROTON-CONDUCTING POLYMER | NIPPON STREEL CHEMICAL CO., LTD (JP) | 2010-03-11 | — | — | US | disclosed |
| US-20100063249-A1 | PROTON-CONDUCTING COMPOUND AND PROTON-CONDUCTING POLYMER | NIPPON STREEL CHEMICAL CO., LTD (JP) | 2010-03-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100063249-A1 | PROTON-CONDUCTING COMPOUND AND PROTON-CONDUCTING POLYMER | HRH3, H1-3, H1-4 | LMNA 1956/4885MEN1 27/4885KMT2A 799/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.